This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Hyperion Therapeutics Appoints Daniel G. Welch To Board Of Directors

Stocks in this article: HPTX

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that it has named Daniel G. Welch to its Board of Directors. Mr. Welch currently serves as Chairman, Chief Executive Officer and President of InterMune, Inc., a public biotechnology company based in Brisbane, California.

"We expect that Dan's breadth of experience successfully leading commercial stage pharmaceutical and biotechnology companies will complement the expertise resident in our board and management team. As we approach our fourth quarter PDUFA date, we are actively planning for the potential launch of Ravicti™, and look forward to Dan's contributions in this critical effort." said Donald J. Santel, Chief Executive Officer of Hyperion.

Mr. Welch has more than 30 years of experience in the biotechnology and pharmaceutical industries. Prior to InterMune, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., from 2002 to 2003. From 2000 to 2002, Welch served as President of the pharmaceutical division at Elan, plc., and from 1987 to 2000, Mr. Welch served in various senior management roles at Sanofi-Synthelabo (now Sanofi-Aventis) and its predecessor companies Sanofi and Sterling Winthrop. There, while serving as Vice President of Worldwide Marketing, he led the successful worldwide launches of several leading products, notably Plavix®, Avapro®, Eloxatin®. From 1980 to 1987, Welch was with American Critical Care, a division of American Hospital Supply. He currently serves on the board of directors for Seattle Genetics, a biotechnology company and also serves on the board of directors for a privately held company. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina.

About Hyperion Therapeutics

Hyperion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion Therapeutics is developing Ravicti™ (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders and hepatic encephalopathy.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs